

## Special Issue

# Evolution of Treatment and Predictive Factors in SCCHN

### Message from the Guest Editor

*Cancers* will hold a Special Issue on squamous cell carcinoma of the head and neck (SCCHN). This Special Issue is dedicated to discussing current standard practices and future perspectives in treatment and predictive factors in SCCHN. The articles included herein cover a broad range of topics, with the goal being to provide a comprehensive overview of the state-of-the-art knowledge related to SCCHN. In this Special Issue, “Evolution of treatment and predictive factors in SCCHN”, authors are invited to contribute cutting-edge studies that will further highlight the contents of immunotherapy, targeted therapy and prognostic markers in SCCHN. I would be honored to have you collaborate for this Special Edition. Specifically, and knowing some of your work, I would like to discuss further initiatives that are not yet published and could be included in this journal. Evidently, any work will require revisions by the standards established by the journal.

### Guest Editor

Prof. Dr. Denis Soulieres

Centre de recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM) and Institut du cancer de Montréal, Montréal, Québec, Canada

### Deadline for manuscript submissions

closed (5 June 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/77437](https://mdpi.com/si/77437)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)